Jingwu Zhang Zang
Director/Board Member presso HH&L ACQUISITION CO.
Patrimonio netto: 8 M $ in data 31/03/2024
Profilo
Fondatore di I-Mab e I-Mab Biopharma (Shanghai) Co., Ltd., Jing Wu Zang è presidente di I-Mab e presidente e amministratore delegato di I-Mab Biopharma (Shanghai) Co. Ltd. (una filiale di I-Mab). Il Dr. Zang è anche nel consiglio di amministrazione di HH&L Acquisition Co. Nella sua carriera passata il Dr. Zang è stato presidente e direttore scientifico di Simcere Pharmaceutical Group Ltd., presidente e direttore scientifico di BioSciKin Co., Ltd., direttore dell'Istituto di immunologia di Shanghai Jiaotong University School of Medicine, vicepresidente senior, responsabile della ricerca e sviluppo di Glaxosmithkline China Ltd., direttore di Opexa Pharmaceuticals, Inc. e professore al Baylor College of Medicine. Jing Wu Zang ha ricevuto un dottorato dalla Shanghai Jiao Tong University e un dottorato dalla Vrije Universiteit Brussel.
Partecipazioni note in società pubbliche
| Società | Data | Numero di azioni | Valorizzazione | Data di valutazione |
|---|---|---|---|---|
I-MAB
4.98% | 31/12/2023 | 9 449 021 ( 4.98% ) | 8 M $ | 31/03/2024 |
Posizioni attive di Jingwu Zhang Zang
| Società | Posizione | Inizio |
|---|---|---|
| HH&L ACQUISITION CO. | Director/Board Member | 04/02/2021 |
I-MAB Biopharma Co., Ltd.
 I-MAB Biopharma Co., Ltd. BiotechnologyHealth Technology I-Mab Biopharma (Shanghai) Co., Ltd. engages in the development of biologics. It focuses on monoclonal antibodies or bi-specific antibodies in the areas of immuno-oncology and autoimmune diseases. The company was founded by Jingwu Zang in March 2017 and is headquartered in Shanghai, China. | Founder | 01/06/2016 |
Precedenti posizioni note di Jingwu Zhang Zang
| Società | Posizione | Fine |
|---|---|---|
| I-MAB | Chief Executive Officer | 30/09/2022 |
| SIMCERE PHARMACEUTICAL GROUP LIMITED | President | 01/04/2016 |
BioSciKin Co., Ltd.
 BioSciKin Co., Ltd. Pharmaceuticals: MajorHealth Technology BioSciKin Co., Ltd. develops drugs and medical products. The private company is based in Nanjing, China. | President | 01/04/2016 |
| Glaxosmithkline China Ltd. | Chief Tech/Sci/R&D Officer | 01/06/2013 |
| Shanghai Jiao Tong University School of Medicine | Corporate Officer/Principal | 01/04/2007 |
Formazione di Jingwu Zhang Zang
| Shanghai Jiao Tong University | Doctorate Degree |
| Vrije Universiteit Brussel | Doctorate Degree |
Esperienze
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
| Società quotate in Borsa | 2 |
|---|---|
| SIMCERE PHARMACEUTICAL GROUP LIMITED | Health Technology |
| I-MAB | Health Technology |
| Aziende private | 7 |
|---|---|
| Opexa Pharmaceuticals, Inc. | Health Technology |
Institut Pasteur de Shanghai
 Institut Pasteur de Shanghai Miscellaneous Commercial ServicesCommercial Services Institut Pasteur de Shanghai operates as a non-profit life sciences organization. The private company is based in Shanghai, China. | Commercial Services |
| Glaxosmithkline China Ltd. | |
| The Institute of Health Sciences | |
BioSciKin Co., Ltd.
BioSciKin Co., Ltd. Pharmaceuticals: MajorHealth Technology BioSciKin Co., Ltd. develops drugs and medical products. The private company is based in Nanjing, China. | Health Technology |
I-MAB Biopharma Co., Ltd.
I-MAB Biopharma Co., Ltd. BiotechnologyHealth Technology I-Mab Biopharma (Shanghai) Co., Ltd. engages in the development of biologics. It focuses on monoclonal antibodies or bi-specific antibodies in the areas of immuno-oncology and autoimmune diseases. The company was founded by Jingwu Zang in March 2017 and is headquartered in Shanghai, China. | Health Technology |
HH&L Acquisition Co.
 HH&L Acquisition Co. Financial ConglomeratesFinance HH&L Acquisition Co. is a blank check company formed for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization, or similar business combination with one or more businesses. The company was founded on September 4, 2020 and is headquartered in Hong Kong. | Finance |
- Borsa valori
- Insiders
- Jingwu Zhang Zang
